The clinical relevance of memantine use;Kliniczne właściwości memantyny

Psychiatria Polska

Volumn 38, Issue 2, 2004, Pages 321-330

  Sobów, Tomasz ^a  

^a Klin Psychiatrii Wieku Podeszlego   (Poland)

Author keywords

Alzheimer's disease; Clinical trials; Memantine

Indexed keywords

CHOLINESTERASE INHIBITOR; GLUTAMIC ACID; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE;

ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; CLINICAL TRIAL; DISEASE SEVERITY; DRUG USE; EUROPE; HUMAN; NEUROPROTECTION; NEUROTOXICITY; POLAND; PSYCHOSIS; SIDE EFFECT; UNITED STATES;

ALZHEIMER DISEASE; DEMENTIA, VASCULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; MALE; MEMANTINE; POLAND; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, N-METHYL-D-ASPARTATE; TREATMENT OUTCOME; UNITED STATES;

EID: 2342470811     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Wolfson C, Wolfson CB, Asgharian M, M'Lan CM, Ostbye T, Rockwood K, Hogan DB & the Clinical Progression of Dementia Study Group. A reevaluation of the duration of survival after the onset of dementia. N. Engl. J. Med. 2001; 344: 1111-1116.
2. Rozzini R, Sabatini T, Barbisoni P, Bellelli G, Trabucchi M. Dementia is a major predictor of death among the Italian elderly. Neurol. 2000; 54: 1014-1019.
3. Evans DA, Funkenstein HH, Albert MS i in. Prevalence of the Alzheimer's disease in a community population of older persons: higher than previously reported. J. Am. Med. Assoc. 1989; 262: 2551-2556.
4. Bachman DL, Wolf PA, Lin R i in. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham study. Neurol. 1992; 42: 115-119.
5. Katzman R, Kawas C. Epidemiology of dementia and Alzheiemr's disease. W: Terry RD, Katzman R, Bick KL, red. Alzheimer's disease. New York: Raven Press; 1994, s. 105-122.
6. Gabryelewicz T. Rozpowszechnienie zespołów otȩpiennych wśród mieszkańców warszawskiej dzielnicy Mokotów w wieku 65-84 lat. Psychiatr. Pol. 1999; 33: 353-366.
7. Bowen DM, Smith CB, White P. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976; 99: 459-496.
8. Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; II, 1403.
9. Perry EK, Gibson PH, Blessed G. Neurotransmitter enzyme abnormalities in senile dementia. J. Neurol. Sc. 1977; 34: 247-265.
10. Whitehouse PJ, Price DL, Struble RG. Alzheimer's disease and senile dementia: loss of neurons in basal forebrain. Science 1982; 215: 1237-1239.
11. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry 1999; 66: 137-147.
12. Rogers SL, Farlow MR, Doody RS. A 24 week, double-blind, placebo controlled trial of donepezil in patients with Alzheimer's disease. Neurol. 1998; 50: 136-145.
13. Rösler M, Anand R, Cicin-Sain A. Efficacy and safety of rivastigmine in patients with Alzheimer's disease. Brit. Med. J. 1999; 318: 633-638.
14. Wilcock G, Stöffler A, Sahin K, Möbius HJ. Neuroradiological findings and the magnitude of cognitive benefit by memantine treatment: a subgroup analysis of the two placebo-controlled clinical trials in vascular dementia. Eur. Neuropsychopharmacol. 2000; 10 (supl 3): 360.
15. Jonsson L. Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease. Pharmacoecon. 2003; 21: 1025-1037.
16. Sobów T, Kłoszewska I. Koszty leczenia w chorobie Alzheimera - czy stosowanie inhibitorów acetylocholinestazy jest ekonomicznie uzasadnione? Psychiatr. Pol. 1999; 33: 761-767.
17. Watkins JC, Evans RH. Excitatory amino acid transmitters. Ann. Rev. Pharmacol. Toxicol. 1981; 21: 165-204.
18. Greenamyre JT, Maragos WF, Albin RL. Glutamate transmission and toxicity in Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 1988; 12: 421-430.
19. Winblad B, Möbius HJ, Stöffler A. Glutamate receptors as a target for Alzheimer's disease - are clinical results supporting the hope? J. Neural. Transm. 2002; 62: 217-225.
20. Arias C, Arrieta I, Tapia R. Beta-amyloid peptide fragment 25-35 potentiates the calcium-dependent release of excitatory amino acids from depolarized hippocampal slices. J. Neurosc. Res. 1995; 41: 561-566.
21. Lees GJ. Contributory mechanism in the causation of neurodegenerative disorders. Neurosc. 1993; 54: 287-322.
22. Harris ME, Wang Y, Pedigo NW. Amyloid beta peptide (25-35) inhibits Na-dependent glutamate uptake in rat hippocampal astrocyte cultures. J. Neurochem. 1996; 67: 277-286.
23. Wenk GL, Danysz W, Mobley SL. MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur. J. Pharmacol. 1995; 293: 267-270.
24. Kornhuber J, Weller M. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol. Psychiatry 1997; 41: 135-144.
25. Parsons CG, Danysz W, Quack G. Memantine is clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: a review of preclinical data. Neuropharmacol. 1999; 38: 735-767.
26. Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R. Memantine prevents beta-amyloid induced neurotoxicity and learning impairments in rats. Neurobiol. Aging 2002; 23: 23.
27. Danysz W, Möbius HJ, Parsons CG. Memantine provides neuroprotection in animal models at therapeutically relevant doses. Am. J. Geriatr. Psychiatry 2002; 10: 1-12.
28. Ambrozi L, Danielczyk W. Treatment of impaired cerebral function in psychogeriatric patients with memantine: results of a phase II double-blind study. Pharmacopsychiatry 1988; 21: 144-146.
29. Ditzler K. Efficacy and tolerability of memantine in patients with dementia syndrome: a double-blind, placebo controlled trial. Arzneimittelforschung 1991; 41: 773-780.
30. Gortelmeyer R, Erbler H: Memantine in the treatment of mild to moderate dementia syndrome: a double-blind, placebo controlled study. Arzneimittelforschung 1992; 42: 904-913.
31. Winblad B, Poritis N. Memantine in severe dementia: results of the M-best study (benefit and efficacy in severely demented patients during treatment with memantine). Int. J. Geriatr. Psychiatry 1999; 14: 135-146.
32. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 2003; 348: 1333-1341.
33. Hartman S, Mobius H. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int. J. Psychopharm. 2003; 18: 81-85.
34. Farlow M, Tariot P, Grossberg G, van Dyck C, Gergel I, Graham S, Jin J. Memantine/Donepezil dual-therapy is superior to Placebo/Donepezil therapy for moderate to severe Alzheimer's disease. Neurol. 2003; 60 (supl. 10): 412.
35. Orgozozo JM, Rigaud AS, Stöffler A, Möbius HJ, Forette F. Efficacy and safety of memantine in patient with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM300). Stroke 2002; 33: 1834-1839.
36. Wilcock G, Möbius HJ, Stöffler A. A double-blind, placebo-controlled, multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int. Clin. Psychopharmacol. 2002; 17: 297-305.
37. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease. Brit. Med. J. 2000; 321: 1445-1449.
38. Rustembegovic A, Kundurovic Z, Sapcanin A, Sofic E. A placebo-controlled study of memantine (Ebixa) in dementia of Wernicke-Korsakoff syndrome. Med. Arh. 2003; 57: 149-50.
39. Hare W, WoldeMussie E, Lai R, Ton H, Ruiz G, Feldmann B, Wijono M, Chun T, Wheeler L. Efficacy and safety of memantine, an NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey. Surv. Ophthalmol. 2001; 45 (supl. 3): 284-289.
40. Lipton SA. Possible role for memantine in protecting retinal ganglion cells from glaucomatous damage. Surv. Ophthalmol. 2003; 48 (supl. 1): 38-46.
41. Sang CN, Booher S, Gilron I, Parada S, Max MB. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiol. 2002; 96: 1053-1061.
42. Maier C, Dertwinkel R, Mansourian N, Hosbach I, Schwenkreis P, Senne I, Skipka G, Zenz M, Tegenthoff M. Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain - results of a randomized double-blinded, placebo-controlled trial. Pain 2003; 103: 277-283.
43. th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy April 5-8, 2000. Stockholm 2000, s. 228.
44. Feldman H, Gauthier S, Hecker J. A 24 week randomized double blind study of donepezil in moderate to severe Alzheimer's disease. Neurol. 2001; 57: 613-620.
45. Doraiswamy PM, Krishnan KR, Anand R, Sohn H, Danyluk J, Hartman RD, Veach J. Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits? Prog. Neuropsychopharmacol. Biol. Psychiatry 2002; 26: 705-712.
46. Sano M, Emesto C, Thomas RG. A controlled trial of selegiline, alpha tocopherol or both as treatment for Alzheimer's disease. N. Engl. J. Med. 1997; 336: 1216-1222.
47. Sobów T, Kłoszewska I, Karlińska I. Addition of vitamin E to donepezil as a treatment for Alzheimer's disease. Alzheimer Rep. 1999; 2: 143-146.
48. Wimo A, Winblad B, Stöffler A, Wirth Y, Möbius HJ. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoecon. 2003; 21: 327-340.